scholarly journals Human Amniotic Fluid for the Treatment of Hospitalized, Symptomatic, and Laboratory-verified SARS-CoV-2 Patients

2021 ◽  
Vol 9 (1) ◽  
pp. 36-39
Author(s):  
Mojgan Barati ◽  
Fakher Rahim
Keyword(s):  
Amniotic Fluid ◽  
Health System ◽  
Vertical Transmission ◽  
Fibrotic Response ◽  
Human Amniotic Fluid ◽  
Novel Therapy ◽  
Limited Access

New reports offer evidence that under different circumstances, intrauterine mother-infant transmission of SARS-CoV-2 occurs. In contrast, early observations in the COVID-19 pandemic recommended that vertical transmission from women infected with SARS-CoV-2 can be challenging and no virus is detected in human amniotic fluid (HAF). The present study aimed to propose the idea that HAF can be used as a potential therapy for hospitalized, symptomatic, and laboratory-verified SARS-CoV-2 patients by mitigating COVID-19 related inflammation and decreasing its fibrosis. Considering that COVID-19 can cause a severe pulmonary fibrotic response in some patients, HAF by decreasing fibrosis may be considered as an alternative and novel therapy against COVID-19. Lastly, given the inexpensive, easy to access, and safe nature of HAF, integrating this therapy may decrease the COVID-19 attributed death and burden to the health system, especially in countries with limited access to vaccines where HAF is widely available.

scholarly journals Condrogenesis of mesenchymal stem cells derived from human amniotic fluid in chitosan-xanthan scaffolds under TGF- beta 3 stimuli

2019 ◽  
Vol 27 ◽  
pp. S433-S434
Author(s):  
I.I. Damas ◽  
C.C. Zuliani ◽  
Â.M. Moraes ◽  
C.B. Westin ◽  
K.C. Andrade ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Amniotic Fluid ◽  
Tgf Beta ◽  
Human Amniotic Fluid

scholarly journals LB20. Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S1002-S1002 ◽  
Author(s):  
Keren Shahar-Nissan ◽  
Joseph Pardo ◽  
Orit Peled ◽  
Irit Krause ◽  
Efraim Bilavsky ◽  
...  
Keyword(s):  
Amniotic Fluid ◽  
Vertical Transmission ◽  
Primary Infection ◽  
Antiviral Drug ◽  
First Trimester ◽  
Controlled Study ◽  
Therapeutic Drug ◽  
Control Group ◽  
Cmv Infection ◽  
In Pregnancy

Abstract Background Cytomegalovirus (CMV) is the most common cause of congenital infection in humans. The highest risk of fetal injury follows a maternal primary infection early in pregnancy. Despite the potential for severe fetal injury, to date there are no proven means to prevent viral transmission. Valacyclovir is an antiviral drug proven effective in decreasing the risk for CMV infection among transplant recipients. Valacyclovir is safe for use in pregnancy, and concentrates in the amniotic fluid without accumulating. A dose of 8 g/day creates therapeutic drug levels in the amniotic fluid and fetal blood. Methods This is a randomized, double-blind, placebo-controlled study comprising pregnant women with serologic evidence of primary CMV infection during the periconceptional period and first trimester. After informed consent, patients were randomly assigned to a treatment group (8 g/day of Valacyclovir) or control group (placebo). Treatment was initiated at the time of serological detection, and continued until amniocentesis. The primary endpoint was the rate of vertical transmission of CMV—determined by amniotic fluid CMV PCR. Secondary endpoints included evidence of symptomatic congenital CMV infection—in utero or postnatally. Results One hundred women were recruited, 90 were included in the data analysis; 45 patients received Valacyclovir and 45 placebo. There were 2 twin pregnancies, and therefore 92 amniocentesis Amongst the Valacyclovir group, 5 (11.1%) amniocentesis were positive for CMV, compared with 14 (29.8%) in the placebo group (P GLMM = 0.03), corresponding with an odds ratio of 0.29 (95% CI: 0.09–0.90) for vertical CMV transmission. Amongst patients infected during the first trimester, a positive amniocentesis for CMV was significantly (P = 0.02) less likely in the Valacyclovir arm (2/19) compared with placebo (11/23). No significant differences (P = 0.91) in CMV-positive amniocentesis were observed between study arms amongst patients infected periconceptionally. Conclusion Valacyclovir at a dose of 8 g/day is effective in reducing the rate of fetal CMV infection following early maternal primary infection during pregnancy. The drug reduces the rate of fetal infection by 71%. Disclosures All authors: No reported disclosures.

Optical Properties of Human Amniotic Fluid: Implications for Videofetoscopic Surgery

2010 ◽  
Vol 27 (2) ◽  
pp. 87-90 ◽  
Author(s):  
Shaun A. Steigman ◽  
Shaun M. Kunisaki ◽  
Louise Wilkins-Haug ◽  
Tamara C. Takoudes ◽  
Dario O. Fauza
Keyword(s):  
Optical Properties ◽  
Amniotic Fluid ◽  
Human Amniotic Fluid

Amniotic fluid LPCAT1 mRNA correlates with the lamellar body count

2016 ◽  
Vol 44 (5) ◽  
Author(s):  
Robert A. Welch ◽  
Michael K. Shaw ◽  
Kathryn C. Welch
Keyword(s):  
Amniotic Fluid ◽  
Pulmonary Surfactant ◽  
Short Communication ◽  
Lamellar Body ◽  
Future Research ◽  
Mrna Levels ◽  
Phospholipid Biosynthesis ◽  
Human Amniotic Fluid ◽  
Perinatal Medicine ◽  
Body Count

AbstractLysophosphatidylcholine acyltransferase 1 (LPCAT1) is required in the biosynthesis of pulmonary surfactant. This short communication describes our assessment of LPCAT1 mRNA levels in human amniotic fluid. We found a direct correlation between LPCAT1 mRNA copies and the amniotic fluid lamellar body count (LBC). This finding corroborates an association between LPCAT1 and surfactant phospholipid biosynthesis in humans. It may provide a model for future research in perinatal medicine.

scholarly journals Human Amniotic Fluid Mesenchymal Stem Cells from Second- and Third-Trimester Amniocentesis: Differentiation Potential, Molecular Signature, and Proteome Analysis

2015 ◽  
Vol 2015 ◽  
pp. 1-15 ◽  
Author(s):  
Jurate Savickiene ◽  
Grazina Treigyte ◽  
Sandra Baronaite ◽  
Giedre Valiuliene ◽  
Algirdas Kaupinis ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Amniotic Fluid ◽  
Expression Patterns ◽  
Specific Gene ◽  
Specific Cell ◽  
Third Trimester ◽  
Human Amniotic Fluid ◽  
Differentiation Potential

Human amniotic fluid stem cells have become an attractive stem cell source for potential applications in regenerative medicine and tissue engineering. The aim of this study was to characterize amniotic fluid-derived mesenchymal stem cells (AF-MSCs) from second- and third-trimester of gestation. Using two-stage protocol, MSCs were successfully cultured and exhibited typical stem cell morphological, specific cell surface, and pluripotency markers characteristics. AF-MSCs differentiated into adipocytes, osteocytes, chondrocytes, myocytes, and neuronal cells, as determined by morphological changes, cell staining, and RT-qPCR showing the tissue-specific gene presence for differentiated cell lineages. Using SYNAPT G2 High Definition Mass Spectrometry technique approach, we performed for the first time the comparative proteomic analysis between undifferentiated AF-MSCs from late trimester of gestation and differentiated into myogenic, adipogenic, osteogenic, and neurogenic lineages. The analysis of the functional and expression patterns of 250 high abundance proteins selected from more than 1400 demonstrated the similar proteome of cultured and differentiated AF-MSCs but the unique changes in their expression profile during cell differentiation that may help the identification of key markers in differentiated cells. Our results provide evidence that human amniotic fluid of second- and third-trimester contains stem cells with multilineage potential and may be attractive source for clinical applications.

Sign in / Sign up

Export Citation Format

Share Document